10:02 AM EDT, 05/28/2025 (MT Newswires) -- Alvotech ( ALVO ) and Advanz Pharma said Wednesday they have signed an agreement to expand their commercial partnership to cover three additional biosimilar candidates in Europe.

The deal covers the supply and commercialization of biosimilar candidates to Ilaris, which is used to treat inflammatory diseases, and Kesimpta, an antibody used to treat relapsing forms of multiple sclerosis, the companies said, adding there's a third undisclosed biosimilar candidate.

The agreement includes development and commercial milestones for the three products of up to $180 million, the companies said, adding that partners will also participate in a revenue share.

Alvotech ( ALVO ) will be in charge of the development and commercial supply, while Advanz will handle registration and commercialization, the companies said.

Price: 11.32, Change: -0.01, Percent Change: -0.09